Mirae Asset Global ETFs Holdings
PTGX icon

Mirae Asset Global ETFs Holdings’s Protagonist Therapeutics PTGX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.84M Buy
31,377
+773
+3% +$80.7K ﹤0.01% 965
2026
Q1 		$3.21M Sell
30,604
-185
-0.6% -$16.4K ﹤0.01% 980
2025
Q4 		$2.69M Sell
30,789
-82
-0.3% -$6.71K ﹤0.01% 1020
2025
Q3 		$2.05M Sell
30,871
-4,970
-14% -$282K ﹤0.01% 1141
2025
Q2 		$1.98M Sell
35,841
-1,562
-4% -$75K ﹤0.01% 1108
2025
Q1 		$1.81M Buy
37,403
+348
+0.9% +$14.6K ﹤0.01% 1198
2024
Q4 		$1.43M Buy
37,055
+1,550
+4% +$67.6K ﹤0.01% 1349
2024
Q3 		$1.6M Buy
35,505
+3,385
+11% +$137K ﹤0.01% 1268
2024
Q2 		$1.11M Buy
+32,120
New +$941K ﹤0.01% 1403

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's PTGX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Protagonist Therapeutics (PTGX) stake by 2.5% in Q2 2026, buying an estimated $80.7K and bringing the position to 31,377 shares worth $3.84M. The position accounts for ﹤0.01% of the portfolio, ranked #965.

Mirae Asset Global ETFs Holdings first reported a position in PTGX in Q2 2024 and has held it in 9 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 31,377 shares of Protagonist Therapeutics worth $3.84M as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 773 Protagonist Therapeutics shares in Q2 2026, an estimated $80.7K.
  • Protagonist Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #965 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.